Zentalis Pharmaceuticals, Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
Zentalis Pharmaceuticals, Inc. (ZNTL) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $808.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-06
- Zentalis Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $2.26M.
- Zentalis Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$1.45M.
- Zentalis Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was -$733.00K.
- Zentalis Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was -$1.98M.
- Zentalis Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was -$17.32M.
- Zentalis Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was -$18.02M, a 265.05% decline from fiscal 2023.
- Zentalis Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $10.92M, a 29.68% decline from fiscal 2022.
- Zentalis Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $15.53M, a 11.19% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $808.00K 10-Q · filed 2026-08-06 | $75.00K derived: sum of 3 quarters · filed 2026-08-06 | -$1.90M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | -$1.45M 10-Q · filed 2026-05-12 | -$2.18M derived: sum of 2 quarters · filed 2026-05-12 | -$4.16M derived: sum of 3 quarters · filed 2026-05-12 | -$14.74M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-12-31 | -$733.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$2.71M derived: sum of 2 quarters · filed 2026-03-26 | -$13.29M derived: sum of 3 quarters · filed 2026-08-06 | -$17.32M 10-K · filed 2026-03-26 | ||
| 2025-09-30 | -$1.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$12.56M derived: sum of 2 quarters · filed 2026-08-06 | -$16.58M 10-Q · filed 2025-11-10 | -$19.14M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-06-30 | -$10.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$14.61M 10-Q · filed 2026-08-06 | -$17.17M derived: sum of 3 quarters · filed 2026-08-06 | -$29.18M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | -$4.02M 10-Q · filed 2026-05-12 | -$6.58M derived: sum of 2 quarters · filed 2026-05-12 | -$18.59M derived: sum of 3 quarters · filed 2026-05-12 | -$6.80M derived: sum of 4 quarters · filed 2026-05-12 | ||
| 2024-12-31 | -$2.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$14.57M derived: sum of 2 quarters · filed 2026-03-26 | -$2.77M derived: sum of 3 quarters · filed 2026-03-26 | -$18.02M 10-K · filed 2026-03-26 | ||
| 2024-09-30 | -$12.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$211.00K derived: sum of 2 quarters · filed 2025-11-10 | -$15.46M 10-Q · filed 2025-11-10 | -$5.06M derived: sum of 4 quarters · filed 2026-03-26 | ||
| 2024-06-30 | $11.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$3.45M 10-Q · filed 2025-08-06 | $6.95M derived: sum of 3 quarters · filed 2026-03-26 | $13.27M derived: sum of 4 quarters · filed 2026-03-26 | ||
| 2024-03-31 | -$15.25M 10-Q · filed 2025-05-14 | -$4.85M derived: sum of 2 quarters · filed 2026-03-26 | $1.48M derived: sum of 3 quarters · filed 2026-03-26 | -$2.92M derived: sum of 4 quarters · filed 2026-03-26 | ||
| 2023-12-31 | $10.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $16.72M derived: sum of 2 quarters · filed 2026-03-26 | $12.33M derived: sum of 3 quarters · filed 2026-03-26 | $10.92M 10-K · filed 2026-03-26 | ||
| 2023-09-30 | $6.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $1.93M derived: sum of 2 quarters · filed 2024-11-12 | $522.00K 10-Q · filed 2024-11-12 | $5.57M derived: sum of 4 quarters · filed 2025-03-26 | ||
| 2023-06-30 | -$4.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | -$5.80M 10-Q · filed 2024-08-09 | -$755.00K derived: sum of 3 quarters · filed 2025-03-26 | $5.70M derived: sum of 4 quarters · filed 2025-03-26 | ||
| 2023-03-31 | -$1.41M 10-Q · filed 2024-05-07 | $3.64M derived: sum of 2 quarters · filed 2025-03-26 | $10.09M derived: sum of 3 quarters · filed 2025-03-26 | $14.62M derived: sum of 4 quarters · filed 2025-03-26 | ||
| 2022-12-31 | $5.05M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $11.50M derived: sum of 2 quarters · filed 2025-03-26 | $16.03M derived: sum of 3 quarters · filed 2025-03-26 | $15.53M 10-K · filed 2025-03-26 | ||
| 2022-09-30 | $6.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $10.98M derived: sum of 2 quarters · filed 2023-11-06 | $10.48M 10-Q · filed 2023-11-06 | $12.13M derived: sum of 4 quarters · filed 2024-02-27 | ||
| 2022-06-30 | $4.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $4.03M 10-Q · filed 2023-08-09 | $5.68M derived: sum of 3 quarters · filed 2024-02-27 | $13.15M derived: sum of 4 quarters · filed 2024-02-27 | ||
| 2022-03-31 | -$500.00K 10-Q · filed 2023-05-10 | -$574.00K 10-Q · filed 2022-05-05 | $1.15M derived: sum of 2 quarters · filed 2024-02-27 | $8.63M derived: sum of 3 quarters · filed 2024-02-27 | $10.16M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2021-12-31 | $1.65M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $9.13M derived: sum of 2 quarters · filed 2024-02-27 | $10.66M derived: sum of 3 quarters · filed 2024-02-27 | $13.96M 10-K · filed 2024-02-27 | $13.92M 10-K · filed 2022-02-24 | |
| 2021-09-30 | $7.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $9.00M derived: sum of 2 quarters · filed 2022-11-09 | $12.31M 10-Q · filed 2022-11-09 | $17.57M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2021-06-30 | $1.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $4.84M 10-Q · filed 2022-08-09 | $10.10M derived: sum of 3 quarters · filed 2023-03-01 | $17.93M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2021-03-31 | $3.31M 10-Q · filed 2022-05-05 | $8.56M derived: sum of 2 quarters · filed 2023-03-01 | $16.40M derived: sum of 3 quarters · filed 2023-03-01 | $17.56M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2020-12-31 | $5.26M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $13.10M derived: sum of 2 quarters · filed 2023-03-01 | $14.25M derived: sum of 3 quarters · filed 2023-03-01 | $14.31M 10-K · filed 2023-03-01 | ||
| 2020-09-30 | $7.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $9.00M derived: sum of 2 quarters · filed 2021-11-10 | $9.05M 10-Q · filed 2021-11-10 | $11.02M derived: sum of 4 quarters · filed 2022-02-24 | ||
| 2020-06-30 | $1.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $1.21M 10-Q · filed 2021-08-12 | $3.18M derived: sum of 3 quarters · filed 2022-02-24 | $5.63M derived: sum of 4 quarters · filed 2022-02-24 | ||
| 2020-03-31 | $53.00K 10-Q · filed 2021-05-17 | $2.02M derived: sum of 2 quarters · filed 2022-02-24 | $4.47M derived: sum of 3 quarters · filed 2022-02-24 | $7.64M derived: sum of 4 quarters · filed 2022-02-24 | ||
| 2019-12-31 | $1.97M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $4.42M derived: sum of 2 quarters · filed 2022-02-24 | $7.59M derived: sum of 3 quarters · filed 2022-02-24 | $7.12M 10-K · filed 2022-02-24 | ||
| 2019-09-30 | $2.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $5.62M derived: sum of 2 quarters · filed 2020-11-09 | $5.16M 10-Q · filed 2020-11-09 | |||
| 2019-06-30 | $3.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | $2.70M 10-Q · filed 2020-08-13 | ||||
| 2019-03-31 | -$467.00K 10-Q · filed 2020-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |